Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral. Analyst Price Forecast Suggests 68.61% Upside As of May 7, 2025, the average ...

Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales ...

How Do Unusual Items Influence Profit? To properly understand Globus Medical's profit results, we need to consider the US$200m expense attributed to unusual items. While deductions due to unusual ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $82.00, and a low estimate of $68.00. A negative shift in sentiment is ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

Lazard Asset Management LLC decreased its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (BMV:GMED) from Buy to Neutral. There are 759 funds or institutions reporting positions in Globus Medical.

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “neutral” rating restated by analysts at BTIG Research in a research report issued on Tuesday, Marketbeat Ratings reports.